Drug research companies Domainex and Auspherix have announced new data in their development of drugs to tackle the growing threat of resistance to antibiotics.
The exciting data, disclosed yesterday (Monday 11th September) in a presentation by Dr Jonathan Powell from Essex-based Domainex at the 19th RSC/SCI Medicinal Chemistry Symposium in Cambridge, described the discovery of three distinct chemical series, all with broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria.
Importantly, the Auspherix compounds are active against so-called ESKAPE pathogens (six pathogens that are developing drug resistance) which are responsible for the majority of hospital infections.
Founding research behind Midlands-based
The focus of the collaboration with Domainex has been to develop novel organogold compounds with activity against Gram-negative bacteria and deliver a novel class of broad-spectrum antibiotics.
Using their medicinal chemistry expertise, the teams at Domainex and Auspherix have explored the Structure-Activity-Relationships (SAR) of the two ligands coordinated to the central gold atom and have found that the phosphine ligand
Robust synthetic routes are now in place to enable the team to further explore the chemical space around this organogold chemical template.
Tom Mander, chief operating officer of Domainex, said, “As far as we know, we are the only teams working on the challenging task of developing broad-spectrum antibiotics based on organogold chemistry.
“In our collaboration with Auspherix, we have made tremendous progress towards identifying novel pre-clinical drug candidates that address the growing global burden of multi-drug resistant bacterial infections.”
Dr Neil Miller,
“We anticipate progressing into human clinical studies in 2019, with an initial focus on the treatment of complicated urinary tract infections (cUTI).”
“Given that our organogold compounds retain activity against multi-drug resistant (MDR) clinical isolates and they show a low propensity for the emergence of resistance, they have great potential to address the greatest unmet medical need and treat patients suffering from life-threatening drug-resistant infections.”
There is a well-defined clinical and regulatory path to approval for new antibiotic treatments for cUTIs with the opportunity to receive Qualified Infectious Disease Product (QIDP) designation, which offers fast-track status and priority review with the FDA, plus potentially five years’ additional market exclusivity, thus making our focus on cUTIs an attractive investment proposition.”